These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24600269)

  • 1. Emerging treatment options in bipolar disorder in adolescents: focus on ziprasidone.
    Khan AA; Strawn JR; Croarkin PE
    Adolesc Health Med Ther; 2010; 1():137-43. PubMed ID: 24600269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ziprasidone in the treatment of mania in bipolar disorder.
    Nicolson SE; Nemeroff CB
    Neuropsychiatr Dis Treat; 2007 Dec; 3(6):823-34. PubMed ID: 19300617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Guidelines for the prescription of mood stabilizers for adolescents: A literature review].
    Munch G; Godart N
    Encephale; 2017 Oct; 43(5):464-470. PubMed ID: 27871720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 26-Week Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Most Recent Episode Manic).
    Atkinson S; Bachinsky M; Raiter Y; Abreu P; Ianos C; Chappell P; Findling RL
    J Child Adolesc Psychopharmacol; 2022 Oct; 32(8):453-458. PubMed ID: 36282771
    [No Abstract]   [Full Text] [Related]  

  • 7. The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.
    Lee HB; Yoon BH; Kwon YJ; Woo YS; Lee JG; Kim MD; Bahk WM
    Clin Drug Investig; 2013 Oct; 33(10):743-53. PubMed ID: 23990283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder.
    Findling RL; Cavuş I; Pappadopulos E; Vanderburg DG; Schwartz JH; Gundapaneni BK; DelBello MP
    J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):545-57. PubMed ID: 24111980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ziprasidone-associated mania: a case series and review of the mechanism.
    Baldassano CF; Ballas C; Datto SM; Kim D; Littman L; O'Reardon J; Rynn MA
    Bipolar Disord; 2003 Feb; 5(1):72-5. PubMed ID: 12656943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of bipolar mania with atypical antipsychotics.
    Chengappa KN; Suppes T; Berk M
    Expert Rev Neurother; 2004 Nov; 4(6 Suppl 2):S17-25. PubMed ID: 16279862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bipolar II disorder : epidemiology, diagnosis and management.
    Benazzi F
    CNS Drugs; 2007; 21(9):727-40. PubMed ID: 17696573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.
    Camm AJ; Karayal ON; Meltzer H; Kolluri S; O'Gorman C; Miceli J; Tensfeldt T; Kane JM
    CNS Drugs; 2012 Apr; 26(4):351-65. PubMed ID: 22452529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder.
    Bowden CL
    J Clin Psychiatry; 2005; 66 Suppl 3():12-9. PubMed ID: 15762830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder.
    Zhu B; Kulkarni PM; Stensland MD; Ascher-Svanum H
    Curr Med Res Opin; 2007 Nov; 23(11):2805-14. PubMed ID: 17910804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatments for late-life bipolar disorder.
    Aziz R; Lorberg B; Tampi RR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):347-64. PubMed ID: 17296540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical Anti-Psychotics in Adult Bipolar Disorder: Current Evidence and Updates in the NICE guidelines.
    Poo SX; Agius M
    Psychiatr Danub; 2014 Nov; 26 Suppl 1():322-9. PubMed ID: 25413559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
    Bowden CL; Vieta E; Ice KS; Schwartz JH; Wang PP; Versavel M
    J Clin Psychiatry; 2010 Feb; 71(2):130-7. PubMed ID: 20122373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder.
    DelBello MP; Versavel M; Ice K; Keller D; Miceli J
    J Child Adolesc Psychopharmacol; 2008 Oct; 18(5):491-9. PubMed ID: 18928413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziprasidone: the fifth atypical antipsychotic.
    Caley CF; Cooper CK
    Ann Pharmacother; 2002 May; 36(5):839-51. PubMed ID: 11978164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focus on ziprasidone: a review of its use in child and adolescent psychiatry.
    Elbe D; Carandang CG
    J Can Acad Child Adolesc Psychiatry; 2008 Nov; 17(4):220-9. PubMed ID: 19018327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.